[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 5 sources · 5 days · First seen · Last updated

Elanco Animal Health corporate activity

Overview

In early August 2026, institutional investors increased their holdings in Elanco Animal Health, with Defilade Capital Management boosting its stake by 132% to about 0.19% of the company. Several other firms also raised their positions, lifting overall institutional ownership to roughly 97.5%. Around the same time, CEO Jeffrey N. Simmons purchased nearly 5,000 shares, bringing his personal stake to about $3.45 million.

A few days later, Elanco announced an upward revision of its 2026 revenue outlook, now forecasting $5.09‑$5.14 billion and a higher innovation‑revenue target. The company cited a 12% year‑over‑year rise in pet‑health revenue, driven by increased demand for tick‑preventive treatments and a new dermatology product gaining significant market share in Europe. The earnings lift was mirrored by strong results across the broader animal‑health sector.

Entities

Elanco Animal Health · NewEdge Advisors LLC · Root Financial Partners LLC · Defilade Capital Management L.P. · Jeff Simmons

Timeline

  1. 8 days ago

    [BUSINESS] 3 sources
    Elanco Animal Health lifts earnings outlook on surge in tick‑related demand

    Elanco Animal Health raised its 2026 revenue outlook to $5.09‑$5.14 billion, citing a tick‑bite driven surge in preventive pet‑health demand; peers also reported resilient earnings.

  2. 12 days ago

    [BUSINESS] 2 sources
    Elanco Animal Health draws sizable institutional investment and CEO share purchase

    Defilade Capital boosted its Elanco stake to 0.19% and other institutions raised holdings, while CEO Jeffrey Simmons bought nearly 5,000 shares, lifting his ownership to $3.45 million.

Sources

empleo.com · it-boltwise.de · labpeople.com · mommygearest.com · stocknews.com